Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 7/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23080272 | 0.87 | CDK1 (0.53) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL23080242 | 0.84 | CCNB2 (0.48) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL21283410 | 0.84 | TMIGD3 (0.52) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL20008058 | 0.82 | CDK1 (0.55) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL27430176 | 0.79 | CDK1 (0.63) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL22214990 | 0.77 | CDK1 (0.55) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL20008037 | 0.77 | ATG7 (0.40) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL20007970 | 0.75 | DNPH1 (0.38) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL21450235 | 0.75 | NT5E (0.54) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL20008098 | 0.73 | CDK1 (0.41) | CDK1CCNB2CCNB1CCNB3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | CDK1 4/4885CCNB2 485/4885CCNB1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.